Back to top
more

Inventiva (IVA)

(Delayed Data from NSDQ)

$2.11 USD

2.11
5,387

-0.05 (-2.32%)

Updated Aug 9, 2024 03:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Inventiva S.A. Sponsored ADR [IVA]

Reports for Purchase

Showing records 1 - 20 ( 81 total )

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

04/01/2024

Company Report

Pages: 6

FY2023 Recap; LPFV in NATiV3 Trial On Target in 1H24; LEGEND Shows Key Data in T2D Patients With MASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

03/20/2024

Company Report

Pages: 9

LEGEND Interim Data in T2D Patients With MASH Are Broadly Positive; Phase 3 NATiV3 LPFV On Target in 1H24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

03/08/2024

Daily Note

Pages: 5

Voluntary Pause on Pivotal NATiV3 Lifted; Patient Screening Has Resumed; Study Timeline Unaffected; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

02/20/2024

Company Report

Pages: 6

Phase 3 NATiV3 Enrollment Temporarily Paused Due to a SUSAR Event; LPFV Now Expected in 2Q24; Moderating PT to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

01/23/2024

Industry Report

Pages: 6

Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

12/21/2023

Company Report

Pages: 6

Topline Results of Phase 3 NATiV3 Study Delayed Another Six Months to 1H26; Other Business Updates; Reduce PT to $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

12/20/2023

Daily Note

Pages: 4

We are updating our Healthcare coverage to reflect a recent analyst departure and to drop

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

10/25/2023

Daily Note

Pages: 4

Biotechnology -Healthcare Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

10/02/2023

Company Report

Pages: 9

1H23 Recap; We Continue to Expect NATiV3''s Top-line Readout in 2H25; Adding Major Asian Markets to Our Model; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

09/21/2023

Daily Note

Pages: 3

Lanifibranor Enters Two Sizable NASH Markets With Partnership; NATiV3''s LPFV in 2H23 As Next Milestone; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

09/21/2023

Daily Note

Pages: 11

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

09/20/2023

Company Report

Pages: 4

Hepalys Agreement Expands lani Opportunity into Japan and South Korea

Provider: Roth Capital Partners, Inc.

Analyst: DUPUIS D

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

09/07/2023

Daily Note

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

09/06/2023

Daily Note

Pages: 4

Capital Raise Extends Cash Runway Into 2Q24

Provider: Roth Capital Partners, Inc.

Analyst: DUPUIS D

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

07/28/2023

Daily Note

Pages: 4

NATiV3 Trial Now 50% Enrolled With LPFV Expected in 2H23; T2D Status Could Be a Key Baseline Factor; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

07/12/2023

Industry Report

Pages: 5

Pre-IPO Note: Sagimet Biosciences, Inc.

Provider: Roth Capital Partners, Inc.

Analyst: DUPUIS D

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

06/29/2023

Daily Note

Pages: 7

EASL Congress 2023: Day 3 and Day 4 NASH Highlights

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

06/23/2023

Company Report

Pages: 5

EASL updates reveal all things going well for lanifibranor in NASH

Provider: Roth Capital Partners, Inc.

Analyst: DUPUIS D

Price: 5.00

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

06/16/2023

Company Report

Pages: 9

Lanifibranor Shows Impressive Cardiometabolic Benefits and Glycemic Control in Patients With NAFLD and T2D; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Inventiva S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

06/14/2023

Company Report

Pages: 5

Positive Phase 2 NAFLD/T2D Results Reinforce Favorable View on Lani

Provider: Roth Capital Partners, Inc.

Analyst: DUPUIS D

Price: 5.00

Research Provided by a Third Party
// eof